Finerenone

Catalog No.S9702 Batch:S970203

Print

Technical Data

Formula

C21H22N4O3
Molecular Weight 378.42 CAS No. 1050477-31-0
Solubility (25°C)* In vitro DMSO 76 mg/mL (200.83 mM)
Ethanol 10 mg/mL (26.42 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Clear solution
5%DMSO Corn oil
0.5mg/ml Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Finerenone (FIN, BAY 94-8862) is a highly selective and orally available nonsteroidal antagonist of mineralocorticoid receptor (MR) with IC50 of 18 nM. Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
Targets
MR [1]
(Cell-free assay)
18 nM
In vitro

In vitro, Finerenone dose-dependently reduces aldosterone-induced smooth muscle cell (SMC) proliferation and prevents aldosteroneinduced endothelial cell (EC) apoptosis. Finerenone significantly reduces apoptosis of ECs and simultaneously attenuates SMC proliferation, resulting in accelerated endothelial healing and reduced neointima formation of the injured vessels.[2]
In vivo

Finerenone improves endothelial dysfunction through an enhancement in NO bioavailability and a decrease in superoxide anion levels due to an upregulation in SOD activity. This is associated with an increase in renal SOD activity and a reduction of albuminuria.[1]

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    Human coronary artery smooth muscle cells (SMC), human umbilical vein endothelial cells (EC)

  • Concentrations

    1 nM, 10 nM

  • Incubation Time

    24 h

  • Method

    Cells are incubated with aldosterone with or without finerenone for 24 hours after 24 hours of serum-starvation for the assessment of cell proliferation and apoptosis. Immediately prior to the addition of aldosterone, cells are preincubated with finerenone or vehicle for 30 minutes.
Animal Study:

[1]
  • Animal Models

    12-week-old MWF, aged-matched normoalbuminuric Wistar rats

  • Dosages

    10 mg/kg

  • Administration

    Oral gavage

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.